Trial Review

Technical difficulties have been reported by some users of the search function and is being investigated by technical staff. Thank you for your patience and apologies for any inconvenience caused.

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been endorsed by the ANZCTR. Before participating in a study, talk to your health care provider and refer to this information for consumers
Trial details imported from ClinicalTrials.gov

For full trial details, please see the original record at https://clinicaltrials.gov/ct2/show/NCT04776252




Registration number
NCT04776252
Ethics application status
Date submitted
26/02/2021
Date registered
1/03/2021
Date last updated
2/04/2024

Titles & IDs
Public title
Open-label, Follow-up of Doravirine/Islatravir (DOR/ISL 100 mg/0.75mg) for Participants With Human Immunodeficiency Virus-1 (HIV-1) Infection (MK-8591A-033)
Scientific title
A Phase 3 Open-label Rollover Clinical Study of Doravirine/Islatravir (DOR/ISL) Once-daily for the Treatment of HIV-1 Infection in Participants Who Previously Received DOR/ISL in a Phase 2 or Phase 3 DOR/ISL Clinical Study
Secondary ID [1] 0 0
MK-8591A-033
Secondary ID [2] 0 0
8591A-033
Universal Trial Number (UTN)
Trial acronym
Linked study record

Health condition
Health condition(s) or problem(s) studied:
HIV-1 Infection 0 0
Condition category
Condition code
Infection 0 0 0 0
Studies of infection and infectious agents
Infection 0 0 0 0
Other infectious diseases
Infection 0 0 0 0
Sexually transmitted infections

Intervention/exposure
Study type
Interventional
Description of intervention(s) / exposure
Treatment: Drugs - MK-8591A

Experimental: MK-8591A - Fixed dose combination (FDC) tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks.


Treatment: Drugs: MK-8591A
FDC tablet of 100 mg doravirine, 0.75 mg islatravir taken orally, once daily for up to 192 weeks
Intervention code [1] 0 0
Treatment: Drugs
Comparator / control treatment
Control group

Outcomes
Primary outcome [1] 0 0
Participants with serious adverse events (SAEs)
Timepoint [1] 0 0
Up to Week 198
Primary outcome [2] 0 0
Participants who discontinued due to an adverse event (AE)
Timepoint [2] 0 0
Up to Week 192

Eligibility
Key inclusion criteria
- Is currently receiving DOR 100 mg/ISL 0.75 mg adult FDC tablet in an MSD-sponsored
clinical study and has completed the last treatment visit.

- Is considered by the investigator to have derived clinical benefit from receiving
DOR/ISL and for whom further treatment with DOR/ISL is considered clinically
appropriate.

- Female is not pregnant or breastfeeding, and at least one of the following conditions
applies: Is not a woman of childbearing potential (WOCBP); or is a non-pregnant WOCBP
who agrees to the following during the intervention period and for at least 6 weeks
after the last dose of study intervention: Not be sexually active, or if sexually
active, to use an acceptable method of contraception; or is pregnant and continues to
receive study intervention (where allowed by local regulations and as appropriate
based on available data/local standard-of-care guidelines)
Minimum age
18 Years
Maximum age
No limit
Sex
Both males and females
Can healthy volunteers participate?
No
Key exclusion criteria
- Is taking or is anticipated to require any prohibited therapies.

Study design
Purpose of the study
Treatment
Allocation to intervention
N/A
Procedure for enrolling a subject and allocating the treatment (allocation concealment procedures)
Methods used to generate the sequence in which subjects will be randomised (sequence generation)
Masking / blinding
Open (masking not used)
Who is / are masked / blinded?



Intervention assignment
Single group
Other design features
Phase
Phase 3
Type of endpoint/s
Statistical methods / analysis

Recruitment
Recruitment status
Active, not recruiting
Data analysis
Reason for early stopping/withdrawal
Other reasons
Date of first participant enrolment
Anticipated
Actual
15/09/2021
Date of last participant enrolment
Anticipated
Actual
Date of last data collection
Anticipated
15/10/2027
Actual
Sample size
Target
2000
Accrual to date
Final
Recruitment in Australia
Recruitment state(s)
NSW,WA
Recruitment hospital [1] 0 0
Holdsworth House Medical Practice ( Site 0700) - Darlinghurst
Recruitment hospital [2] 0 0
St Vincent's Hospital-IBAC ( Site 0702) - Sydney
Recruitment hospital [3] 0 0
Fiona Stanley Hospital ( Site 0706) - Murdock
Recruitment postcode(s) [1] 0 0
2010 - Darlinghurst
Recruitment postcode(s) [2] 0 0
2010 - Sydney
Recruitment postcode(s) [3] 0 0
6150 - Murdock
Recruitment outside Australia
Country [1] 0 0
United States of America
State/province [1] 0 0
Arizona
Country [2] 0 0
United States of America
State/province [2] 0 0
California
Country [3] 0 0
United States of America
State/province [3] 0 0
District of Columbia
Country [4] 0 0
United States of America
State/province [4] 0 0
Florida
Country [5] 0 0
United States of America
State/province [5] 0 0
Georgia
Country [6] 0 0
United States of America
State/province [6] 0 0
Illinois
Country [7] 0 0
United States of America
State/province [7] 0 0
Missouri
Country [8] 0 0
United States of America
State/province [8] 0 0
New Jersey
Country [9] 0 0
United States of America
State/province [9] 0 0
New York
Country [10] 0 0
United States of America
State/province [10] 0 0
Pennsylvania
Country [11] 0 0
United States of America
State/province [11] 0 0
Texas
Country [12] 0 0
Canada
State/province [12] 0 0
Alberta
Country [13] 0 0
Canada
State/province [13] 0 0
British Columbia
Country [14] 0 0
Canada
State/province [14] 0 0
Ontario
Country [15] 0 0
Canada
State/province [15] 0 0
Quebec
Country [16] 0 0
Chile
State/province [16] 0 0
Araucania
Country [17] 0 0
Chile
State/province [17] 0 0
Region M. De Santiago
Country [18] 0 0
Colombia
State/province [18] 0 0
Valle Del Cauca
Country [19] 0 0
France
State/province [19] 0 0
Alpes-Maritimes
Country [20] 0 0
France
State/province [20] 0 0
Bourgogne
Country [21] 0 0
France
State/province [21] 0 0
Gironde
Country [22] 0 0
France
State/province [22] 0 0
Haute-Garonne
Country [23] 0 0
France
State/province [23] 0 0
Haute-Normandie
Country [24] 0 0
France
State/province [24] 0 0
Herault
Country [25] 0 0
France
State/province [25] 0 0
Ile-de-France
Country [26] 0 0
France
State/province [26] 0 0
Loire-Atlantique
Country [27] 0 0
France
State/province [27] 0 0
Nord
Country [28] 0 0
France
State/province [28] 0 0
Rhone
Country [29] 0 0
France
State/province [29] 0 0
Paris
Country [30] 0 0
Germany
State/province [30] 0 0
Niedersachsen
Country [31] 0 0
Italy
State/province [31] 0 0
Lazio
Country [32] 0 0
Italy
State/province [32] 0 0
Lombardia
Country [33] 0 0
Italy
State/province [33] 0 0
Milano
Country [34] 0 0
Japan
State/province [34] 0 0
Aichi
Country [35] 0 0
Japan
State/province [35] 0 0
Tokyo
Country [36] 0 0
Japan
State/province [36] 0 0
Osaka
Country [37] 0 0
New Zealand
State/province [37] 0 0
Canterbury
Country [38] 0 0
Poland
State/province [38] 0 0
Dolnoslaskie
Country [39] 0 0
Poland
State/province [39] 0 0
Lodzkie
Country [40] 0 0
Poland
State/province [40] 0 0
Mazowieckie
Country [41] 0 0
Russian Federation
State/province [41] 0 0
Kemerovskaya Oblast
Country [42] 0 0
Russian Federation
State/province [42] 0 0
Krasnoyarskiy Kray
Country [43] 0 0
Russian Federation
State/province [43] 0 0
Leningradskaya Oblast
Country [44] 0 0
Russian Federation
State/province [44] 0 0
Moskva
Country [45] 0 0
Russian Federation
State/province [45] 0 0
Sankt-Peterburg
Country [46] 0 0
Russian Federation
State/province [46] 0 0
Smolenskaya Oblast
Country [47] 0 0
Russian Federation
State/province [47] 0 0
Tatarstan, Respublika
Country [48] 0 0
South Africa
State/province [48] 0 0
Free State
Country [49] 0 0
South Africa
State/province [49] 0 0
Gauteng
Country [50] 0 0
South Africa
State/province [50] 0 0
Kwazulu-Natal
Country [51] 0 0
South Africa
State/province [51] 0 0
Western Cape
Country [52] 0 0
Spain
State/province [52] 0 0
Alicante
Country [53] 0 0
Spain
State/province [53] 0 0
Barcelona
Country [54] 0 0
Spain
State/province [54] 0 0
Cataluna
Country [55] 0 0
Spain
State/province [55] 0 0
Madrid, Comunidad De
Country [56] 0 0
Spain
State/province [56] 0 0
Madrid
Country [57] 0 0
Switzerland
State/province [57] 0 0
Aargau
Country [58] 0 0
Switzerland
State/province [58] 0 0
Geneve
Country [59] 0 0
Switzerland
State/province [59] 0 0
Sankt Gallen
Country [60] 0 0
Switzerland
State/province [60] 0 0
Ticino
Country [61] 0 0
Switzerland
State/province [61] 0 0
Zurich
Country [62] 0 0
Switzerland
State/province [62] 0 0
Berne
Country [63] 0 0
United Kingdom
State/province [63] 0 0
Brighton And Hove
Country [64] 0 0
United Kingdom
State/province [64] 0 0
Bristol, City Of
Country [65] 0 0
United Kingdom
State/province [65] 0 0
England
Country [66] 0 0
United Kingdom
State/province [66] 0 0
Manchester

Funding & Sponsors
Primary sponsor type
Commercial sector/Industry
Name
Merck Sharp & Dohme LLC
Address
Country

Ethics approval
Ethics application status

Summary
Brief summary
The safety and tolerability of MK-8591A, a 2-drug fixed dose combination (FDC) of doravirine
(DOR 100mg) and islatravir (ISL 0.75mg) will be evaluated in participants with Human
Immunodeficiency Virus -1 (HIV-1) who were treated with DOR and ISL in earlier clinical
studies.
Trial website
https://clinicaltrials.gov/ct2/show/NCT04776252
Trial related presentations / publications
Public notes

Contacts
Principal investigator
Name 0 0
Medical Director
Address 0 0
Merck Sharp & Dohme LLC
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for public queries
Name 0 0
Address 0 0
Country 0 0
Phone 0 0
Fax 0 0
Email 0 0
Contact person for scientific queries